Recombinant therapeutic proteins degradation and overcoming strategies in CHO cells.
Appl Microbiol Biotechnol
; 108(1): 182, 2024 Jan 29.
Article
em En
| MEDLINE
| ID: mdl-38285115
ABSTRACT
Mammalian cell lines are frequently used as the preferred host cells for producing recombinant therapeutic proteins (RTPs) having post-translational modified modification similar to those observed in proteins produced by human cells. Nowadays, most RTPs approved for marketing are produced in Chinese hamster ovary (CHO) cells. Recombinant therapeutic antibodies are among the most important and promising RTPs for biomedical applications. One of the issues that occurs during development of RTPs is their degradation, which caused by a variety of factors and reducing quality of RTPs. RTP degradation is especially concerning as they could result in reduced biological functions (antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity) and generate potentially immunogenic species. Therefore, the mechanisms underlying RTP degradation and strategies for avoiding degradation have regained an interest from academia and industry. In this review, we outline recent progress in this field, with a focus on factors that cause degradation during RTP production and the development of strategies for overcoming RTP degradation. KEY POINTS ⢠The recombinant therapeutic protein degradation in CHO cell systems is reviewed. ⢠Enzymatic factors and non-enzymatic methods influence recombinant therapeutic protein degradation. ⢠Reducing the degradation can improve the quality of recombinant therapeutic proteins.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Apoptose
/
Indústrias
Limite:
Animals
/
Humans
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article